<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4908">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702958</url>
  </required_header>
  <id_info>
    <org_study_id>R01HL154768-01</org_study_id>
    <secondary_id>R01HL154768-01</secondary_id>
    <nct_id>NCT04702958</nct_id>
  </id_info>
  <brief_title>TRANSFORM-HF Ancillary Mechanistic Study</brief_title>
  <official_title>Mechanistic Insights From Longitudinal Changes in Blood and Urine Proteins to Explain Efficacy and Safety of Torsemide vs Furosemide After a Heart Failure Hospitalization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Mason University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with heart failure are frequently treated with diuretics, including furosemide and&#xD;
      torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is&#xD;
      studying if torsemide is superior than furosemide for reducing the endpoint of death or&#xD;
      hospitalization, but is not designed to study why. This ancillary study seeks to measure&#xD;
      proteins in the blood and urine to help explain the underlying mechanism for why patients who&#xD;
      take one of these diuretics may have better outcomes than patients who take the other.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who are enrolling in the TRANSFORM-HF study will provide blood and urine at the time&#xD;
      of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week)&#xD;
      after hospital discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 10, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in proteomic protein clusters between treatment groups</measure>
    <time_frame>baseline</time_frame>
    <description>How the biomarkers are different between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in trajectories of protein clusters between treatment groups</measure>
    <time_frame>90 days</time_frame>
    <description>How the protein clusters change over time from baseline to 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in single biomarkers and biomarker trajectories between treatment groups</measure>
    <time_frame>baseline and 90 days</time_frame>
    <description>How the biomarkers are different between groups at baseline and how the biomarkers change over time from baseline to 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in urinary protein levels between treatment groups</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Torsemide</arm_group_label>
    <description>Patients enrolled in the TRANSFORM-HF study randomized to Torsemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <description>Patients enrolled in the TRANSFORM-HF study randomized to Furosemide</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Single biomarkers: high sensitive cardiac troponin T (hs-cTnT), amino terminal pro&#xD;
           B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15),&#xD;
           Cystatin C, high sensitive C-reactive protein (hsCRP), and interleukin 6 (IL6).&#xD;
&#xD;
        -  Urinary biomarkers: albumin, beta-2 microglobulin (B2M), cystatin C, epidermal growth&#xD;
           factor (EGF), neutrophil gelatinase-associated lipocalin (NGAL/Lipocalin-2), osteopontin&#xD;
           (OPN), uromodulin (UMOD)&#xD;
&#xD;
        -  Targeted discovery proteomics: Olink CARDIOVASCULAR III (CVD III) panel&#xD;
&#xD;
        -  Covid-19 antibodies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll a subset of patients who are enrolling in the TRANSFORM-HF study&#xD;
        during a hospitalization for acute HF, and who are willing to provide biospecimens for&#xD;
        analysis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in the TRANSFORM-HF trial&#xD;
&#xD;
          -  Willing to provide blood and urine sample at enrollment and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or unwillingness to comply with the study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Cooper, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

